{
    "id": "17982e48-31b2-4b74-896f-b7f61b1e54ad",
    "indications": {
        "text": "bortezomib injection proteasome inhibitor indicated : treatment adult patients multiple myeloma ( 1.1 ) treatment adult patients mantle cell lymphoma ( 1.2 )",
        "doid_entities": [
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "mantle cell lymphoma (DOID:0050746)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050746"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "subcutaneous intravenous . route different reconstituted concentration . exercise caution calculating volume administered . ( 2.1 , 2.10 ) recommended starting dose bortezomib injection 1.3 mg/m 2 administered either 3 5 second bolus intravenous injection subcutaneous injection . ( 2.2 , 2.4 , 2.6 ) retreatment multiple myeloma : may retreat starting last tolerated dose . ( 2.6 ) hepatic impairment : lower starting dose patients moderate severe hepatic impairment . ( 2.8 ) dose must individualized prevent overdose . ( 2.10 )",
        "doid_entities": [
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "bortezomib injection supplied white off-white cake powder . ndc bortezomib injection package factor 25021-262-10 3.5 mg single-dose vial 1 vial per carton",
    "adverseReactions": "bortezomib injection contraindicated patients hypersensitivity ( including local ) bortezomib , boron , mannitol . included anaphylactic [ ( 6.1 ) ] . bortezomib injection contraindicated intrathecal . fatal events occurred intrathecal bortezomib injection .",
    "ingredients": [
        {
            "name": "BORTEZOMIB",
            "code": "69G8BD63PP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_52717"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ],
    "organization": "Sagent Pharmaceuticals",
    "name": "BORTEZOMIB",
    "effectiveTime": "20250505",
    "indications_original": "Bortezomib for Injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )",
    "contraindications_original": "For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. ( 2.1 , 2.10 ) The recommended starting dose of Bortezomib for Injection is 1.3\u00a0mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. ( 2.2 , 2.4 , 2.6 ) Retreatment for Multiple Myeloma: May retreat starting at the last tolerated dose. ( 2.6 ) Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment. ( 2.8 ) Dose must be individualized to prevent overdose. ( 2.10 )",
    "warningsAndPrecautions_original": "Bortezomib for Injection is supplied as a white to off-white cake or powder.\n\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Bortezomib for Injection\n                           \n                           \n                              Package Factor\n                           \n                        \n                        \n                           25021-262-10\n\n                           3.5 mg Single-Dose Vial\n\n                           1 vial per carton",
    "adverseReactions_original": "Bortezomib for Injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [see Adverse Reactions (6.1)].\n\n                  Bortezomib for Injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of Bortezomib for Injection.",
    "drug": [
        {
            "name": "BORTEZOMIB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_52717"
        }
    ]
}